普拉克索联合左旋多巴治疗帕金森病的效果  

Effect of Pramipexole Combined with Levodopa in the Treatment of Parkinson’s Disease

作　　者：安萍 AN Ping(Department of Neurology,the First People's Hospital of Xiaochang County,Xiaochang,Hubei Province,432900 China)

机构地区：[1]湖北省孝昌县第一人民医院神经内科,湖北孝昌432900

出　　处：《中外医疗》2020年第8期85-87,共3页China & Foreign Medical Treatment

摘　　要：目的分析普拉克索联合左旋多巴在治疗帕金森病方面的临床效果。方法研究对象为方便选择该院2017年1月-2018年12月期间所收治的96例帕金森病患者,对其临床资料展开回顾性分析。将患者随机划分为观察组和对照组,每组48例。在确诊后就应该给予早期的保护性治疗,且患者开始用药的时间应该选择疾病早期症状较轻,对日常生活、工作影响程度较小的时间段。如果疾病影响到了患者的正常生活,则需要考虑采取症状性治疗。对照组在此基础上单独使用左旋多巴进行治疗,观察组则在左旋多巴外联用普拉克索。治疗周期结束后按照统一的帕金森病评定量表(UPDRS)Ⅱ评估患者的生活自理能力,利用UPDRS Ⅲ评估患者的运动障碍情况,按照差异来分析不同治疗方案的作用。结果该次研究结果表明,观察组在UPDRS Ⅱ(11.1±3.2)分和UPDRS Ⅲ(28.7±4.1)分的评分上均要优于对照组(13.8±2.9)分、(34.0±3.6)分,数据结果差异有统计学意义(t=3.338、3.405,P<0.05)。结论普拉克索联合左旋多巴在治疗帕金森病方面效果显著,患者的生活质量和自理能力能够恢复至较好的水平,该方法也具有临床推广的价值。Objective To analyze the clinical effect of Pramipexole combined with levodopa in the treatment of Parkinson’s disease. Methods The study subjects convenient selected 96 patients with Parkinson’s disease treated in the hospital from January 2017 to December 2018, and their clinical data were retrospectively analyzed. Patients were randomly divided into observation group and control group, with 48 cases in each group. Early protective treatment should be given after the diagnosis is made, and the time for patients to start medication should be a period of time with less early symptoms of the disease and less impact on daily life and work. If the disease affects the patient’s normal life, then symptomatic treatment needs to be considered. The control group was treated with levodopa alone on the basis of this, while the observation group was treated with pramipexole in combination with levodopa. After the end of the treatment cycle, the patients’ self-care ability was assessed according to the unified Parkinson’s disease rating scale(UPDRS) Ⅱ. The patients’ motor dysfunction was evaluated by UPDRSⅢ, and the effects of different treatment schemes were analyzed according to the differences.Results The results of this study showed that the observation group has better UPDRS Ⅱ(11.1±3.2)points and UPDRSⅢ(28.7±4.1)points than the control group(13.8±2.9)points and(34.0±3.6)points. The data results were significantly different,with statistical significance(t =3.338, 3.405, P <0.05). Conclusion Pramipexole combined with levodopa has a significant effect in the treatment of Parkinson’s disease. The quality of life and self-care ability of patients can be restored to a good level. This method also has clinical value.

关 键 词：普拉克索 左旋多巴 帕金森病 临床疗效 

分 类 号：R742.5[医药卫生—神经病学与精神病学]